CoChat

Rationale for the Development of 2-Aminobenzamide Histone Deacetylase Inhibitors as Therapeutics for Friedreich Ataxia

Open access
Soragni, Elisabetta, Xu, Chunping, Plasterer, Heather L., Jacques, Vincent, Rusche, James R., Gottesfeld, Joel M. · 2012 · Journal of Child Neurology
Cited by 36

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Numerous studies have pointed to histone deacetylase inhibitors as potential therapeutics for various neurodegenerative diseases, and clinical trials with several histone deacetylase inhibitors have been performed or are under way. However, histone deacetylase inhibitors tested to date either are highly cytotoxic or have very low specificities for different histone deacetylase enzymes. The authors’ laboratories have identified a novel class of histone deacetylase inhibitors (2-aminobenzamides) that reverses heterochromatin-mediated silencing of the frataxin ( FXN) gene in Friedreich ataxia. The authors have identified the histone deacetylase enzyme isotype target of these compounds and present evidence that compounds that target this enzyme selectively increase FXN expression from pathogenic alleles. Studies with model compounds show that these histone deacetylase inhibitors increase FXN messenger RNA levels in the brain in mouse models for Friedreich ataxia and relieve neurological symptoms observed in mouse models and support the notion that this class of molecules may serve as therapeutics for the human disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0883073812448533

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Histone deacetylases and cancer: causes and therapies

    Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×

    “This approach has recently been employed for the identification of the histone deacetylase targets of suberoylanilide hydroxamic acid,(54) and histone deacetylases 1 and 2 were identified, as would be expected from previous studies with this compound.(55) Our trifunctional probe (1-BP, Figure 3) consists of a benzophe…”
    Method
  • Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia

    Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., & Gottesfeld, J. M. (2006) · Nature Chemical Biology · doi:10.1038/nchembio815 · Cited by 442 · cited 3×

    “In our study, no significant differences in the levels of histone acetylation were found on the FXN promoter in cell lines from a patient with Friedreich ataxia and those from unaffected individuals.(3) However, the first intron of active FXN alleles in normal cell lines is enriched in acetylated histones H3 and H4, c…”
    BackgroundResultSelf-citation
  • The GAA Triplet-Repeat Expansion in Friedreich Ataxia Interferes with Transcription and May Be Associated with an Unusual DNA Structure

    Bidichandani, S. I., Ashizawa, T., & Patel, P. I. (1998) · The American Journal of Human Genetics · doi:10.1086/301680 · Cited by 381

  • Sticky DNA

    Sakamoto, N., Chastain, P. D., Parniewski, P., Ohshima, K., Pandolfo, M., Griffith, J. D., & Wells, R. D. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80474-8 · Cited by 313

  • Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases

    Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223 · cited 5×

    “We also showed that 106 was a potent inducer of frataxin protein in these cells, but suberoylanilide hydroxamic acid showed no such activity.(48) Thus, the active 2-aminobenzamides differ from hydroxamates in their mechanism of inhibition of class I histone deacetylases, and this difference could well account for the…”
    BackgroundMethodInfluentialSelf-citation
  • Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)

    Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191 · cited 1×

    “This notion was based on molecular modeling, where the 5-phenyl was predicted to clash with a tyrosine found in histone deacetylase 3, where a noninterfering serine would occupy a similar position in histone deacetylase 1/2.(58) This expectation is fully borne out in Ki measurements (Table 1).”
  • Frataxin knockin mouse

    Miranda, C. J., Santos, M. M., Ohshima, K., Smith, J., Li, L., Bunting, M., Cossée, M., Koenig, M., Sequeiros, J., Kaplan, J., et al. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02251-2 · Cited by 172 · cited 1×

    “The homozygous knock-in/knock-in (KIKI, FXN) mouse exhibits *66% of wild-type FXN messenger RNA in the brain and other organs.(47) Characteristic histone modifications occur at expanded alleles in the first intron of the mouse frataxin gene in the KIKI mouse as in cells from patients with Friedreich ataxia(3) and Frie…”
    Background

Show all 7 references

Cited by

See all 36

Metadata

Authors
Soragni, E., Xu, C., Plasterer, H. L., Jacques, V., Rusche, J. R., & Gottesfeld, J. M.
Venue
Journal of Child Neurology
Published
2012-07-04
Volume
27
Issue
9
Pages
1164-1173
ISSN
  • 0883-0738 (ISSN-L)
  • 1708-8283
OpenAlex
W2138702324
Cited by
36
References
7
FWCI
2.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rationale for the Development of 2-Aminobenzamide Histone Deacetylase Inhibitors as Therapeutics for Friedreich Ataxia. https://app.cochat.ai/papers/10.1177/0883073812448533
The paper
Soragni, E., Xu, C., Plasterer, H. L., Jacques, V., Rusche, J. R., & Gottesfeld, J. M. (2012). Rationale for the Development of 2-Aminobenzamide Histone Deacetylase Inhibitors as Therapeutics for Friedreich Ataxia. Journal of Child Neurology. https://doi.org/10.1177/0883073812448533

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.